PODCAST · health
Adopting the Evolving Management of HR+/HER2-mBC into Practice
by Annenberg Center for Health Sciences
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
-
4
Therapeutic Approaches for the Treatment of Patients with HR+/HER2- mBC
Therapeutic Approaches for the Treatment of Patients with HR+/HER2- mBC
-
3
Navigating Through the Current Treatment of Patients with HR+/HER2- mBC
Navigating Through the Current Treatment of Patients with HR+/HER2- mBC
-
2
Molecular and Tumor Profiling
Molecular and Tumor Profiling
-
1
Background and Scope for Management of Patients with HR+/HER2- mBC
Background and Scope for Management of Patients with HR+/HER2- mBC
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.
HOSTED BY
Annenberg Center for Health Sciences
Loading similar podcasts...